Researchers performed a double-blind trial at a tertiary care hospital in India. Patients with cirrhosis who had recovered from an episode of hepatic encephalopathy during the previous month were assigned randomly to groups given a probiotic preparation or placebo daily for six months.
The study found a reduction in the development of breakthrough hepatic encephalopathy among patients receiving the probiotic — 34.8 percent in the probiotic group versus 51.6 percent in the placebo group. Also, fewer patients in the probiotic group were hospitalized for hepatic encephalopathy, 19.7 percent, as compared to 42.2 percent in the placebo group. Only 24.2 percent of patients in the probiotic group were hospitalized for complications of cirrhosis.
More articles on gastroenterology:
Cantel Medical names Jorgen Hansen president, COO
Hanover Gastroenterology expands
GI physician to know: Dr. David Rubin of University of Chicago Medicine
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
